Formulation: A solid
Formal Name: 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl-1,1,2,2-d4]-2-oxo-1H-pyrrole-1-carboxamide
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C24H30D4N4O5S
Formula Weight: 494,6
Shelf life (days): 1460
CAS Number: 2699607-96-8
Notes: Glimepiride-d4 is intended for use as an internal standard for the quantification of glimepiride (Item No. 12090) by GC- or LC-MS. Glimepiride is a long-acting sulfonylurea that inhibits ATP-sensitive potassium (KATP) channels in pancreatic β-cells (IC50 = 3 nM), which leads to the release of insulin.{25521} At 20 μM, glimepiride has been shown to increase the activity of intracellular insulin receptors and to prevent insulin receptor downregulation during chronic insulin stimulation through a mechanism involving protein kinase C activation.{25523} It has been reported to be less effective at inhibiting nonpancreatic KATP channels, and therefore contributes fewer cardiac actions, compared to earlier generations of sulfonylurea anti-type 2 diabetes treatments.{25522}